Human biallelic MFN2 mutations induce mitochondrial dysfunction, upper body adipose hyperplasia, and suppression of leptin expression
- The University of Cambridge Metabolic Research Laboratories, United Kingdom
- University of Pavia, Italy
- University of Birmingham, United Kingdom
- Aarhus University Hospital, Denmark
- UCB Pharma, United Kingdom
- Wellcome Trust Sanger Institute, United Kingdom
- University of Cambridge School of Clinical Medicine, United Kingdom
- Cambridge University Hospitals NHS Foundation Trust, United Kingdom
- University of Copenhagen, Denmark
- Birmingham Women's Hospital, United Kingdom
- UCL Institute of Neurology, United Kingdom
- National Institutes of Health, United States
- University of Maryland School of Medicine, United States
- Brehm Center for Diabetes, United States
- The National Institute for Health Research Cambridge Biomedical Research Centre, United Kingdom
- Aarhus University, Denmark
Abstract
MFN2 encodes mitofusin 2, a membrane-bound mediator of mitochondrial membrane fusion and inter-organelle communication. MFN2 mutations cause axonal neuropathy, with associated lipodystrophy only occasionally noted, however homozygosity for the p.Arg707Trp mutation was recently associated with upper body adipose overgrowth. We describe similar massive adipose overgrowth with suppressed leptin expression in four further patients with biallelic MFN2 mutations and at least one p.Arg707Trp allele. Overgrown tissue was composed of normal-sized, UCP1-negative unilocular adipocytes, with mitochondrial network fragmentation, disorganised cristae, and increased autophagosomes. There was strong transcriptional evidence of mitochondrial stress signalling, increased protein synthesis, and suppression of signatures of cell death in affected tissue, whereas mitochondrial morphology and gene expression were normal in skin fibroblasts. These findings suggest that specific MFN2 mutations cause tissue-selective mitochondrial dysfunction with increased adipocyte proliferation and survival, confirm a novel form of excess adiposity with paradoxical suppression of leptin expression, and suggest potential targeted therapies.
Data availability
-
RNA-seq of overgrown interscapular adipose tissue with biallelic MFN2 mutationsPublicly available at the NCBI Gene Expression Omnibus (accession no: GSE97156).
-
ClinVar: public archive of interpretations of clinically relevant variantsPublicly available at the NCBI ClinVar (accession no: RCV000002369).
-
Exome Aggregation Consortium (ExAC)Publicly available at Broad Institute (accession no: ENSG00000116688).
Article and author information
Author details
Funding
Medical Research Council (MRC_MC_UU_12012/5)
- Nuno M Rocha
Wellcome (Wellcome Trust Postdoctoral Fellowship for Clinicians (10043/Z/15/Z))
- Alex Rossor
National Institute for Health Research (NIHR Clinical Research Facilities for Experimental Medicine Award to Cambridge NIHR/Wellcome Trust)
- Alison Sleigh
National Institute for Health Research (Cambridge BRC and Clinical Research Facility; Rare Disease Translational Research Collaboration)
- Stephen I O'Rahilly
- Eamonn R Maher
- David B Savage
- Robert K Semple
National Institutes of Health (Oxford-Cambridge Scholars Programme)
- David A Bulger
Wellcome (WT098051)
- Felicity Payne
- Inês Barroso
National Institute of Diabetes and Digestive and Kidney Diseases (Intramural research program)
- Elif A Oral
National Institute of Diabetes and Digestive and Kidney Diseases (RO1-DK 08811)
- Elif A Oral
UCB Pharma (Gen 001)
- Hannah Titheradge
- Duncan McHale
- Eamonn R Maher
Medical Research Council (MRC Centre grant (G0601943))
- Mary Reilly
National Institutes of Neurological Diseases and Stroke and office of Rare Diseases (U54NS065712)
- Mary Reilly
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Ethics
Human subjects: Written informed consent was obtained from all participants or their parents if under 18 years old for the research described and for publication of results. The research was approved by the Cambridgeshire South Research Ethics Committee, Reference no. 12/EE/0405
Copyright
This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Metrics
-
- 3,612
- views
-
- 804
- downloads
-
- 67
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Human biallelic MFN2 mutations induce mitochondrial dysfunction, upper body adipose hyperplasia, and suppression of leptin expression
eLife 6:e23813.
https://doi.org/10.7554/eLife.23813
Further reading
-
- Cell Biology
Discovering new strategies to combat the multidrug-resistant bacteria constitutes a major medical challenge of our time. Previously, artesunate (AS) has been reported to exert antibacterial enhancement activity in combination with β-lactam antibiotics via inhibition of the efflux pump AcrB. However, combination of AS and colistin (COL) revealed a weak synergistic effect against a limited number of strains, and few studies have further explored its possible mechanism of synergistic action. In this article, we found that AS and EDTA could strikingly enhance the antibacterial effects of COL against mcr-1- and mcr-1+ Salmonella strains either in vitro or in vivo, when used in triple combination. The excellent bacteriostatic effect was primarily related to the increased cell membrane damage, accumulation of toxic compounds and inhibition of MCR-1. The potential binding sites of AS to MCR-1 (THR283, SER284, and TYR287) were critical for its inhibition of MCR-1 activity. Additionally, we also demonstrated that the CheA of chemosensory system and virulence-related protein SpvD were critical for the bacteriostatic synergistic effects of the triple combination. Selectively targeting CheA, SpvD, or MCR using the natural compound AS could be further investigated as an attractive strategy for the treatment of Salmonella infection. Collectively, our work opens new avenues toward the potentiation of COL and reveals an alternative drug combination strategy to overcome COL-resistant bacterial infections.
-
- Cell Biology
- Genetics and Genomics
Progression through the G1 phase of the cell cycle is the most highly regulated step in cellular division. We employed a chemogenetic approach to discover novel cellular networks that regulate cell cycle progression. This approach uncovered functional clusters of genes that altered sensitivity of cells to inhibitors of the G1/S transition. Mutation of components of the Polycomb Repressor Complex 2 rescued proliferation inhibition caused by the CDK4/6 inhibitor palbociclib, but not to inhibitors of S phase or mitosis. In addition to its core catalytic subunits, mutation of the PRC2.1 accessory protein MTF2, but not the PRC2.2 protein JARID2, rendered cells resistant to palbociclib treatment. We found that PRC2.1 (MTF2), but not PRC2.2 (JARID2), was critical for promoting H3K27me3 deposition at CpG islands genome-wide and in promoters. This included the CpG islands in the promoter of the CDK4/6 cyclins CCND1 and CCND2, and loss of MTF2 lead to upregulation of both CCND1 and CCND2. Our results demonstrate a role for PRC2.1, but not PRC2.2, in antagonizing G1 progression in a diversity of cell linages, including chronic myeloid leukemia (CML), breast cancer, and immortalized cell lines.
